A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis.
about
Investigational drugs to treat methicillin-resistant Staphylococcus aureusStaphylococcal manipulation of host immune responsesWill there ever be a universal Staphylococcus aureus vaccine?Where does a Staphylococcus aureus vaccine stand?Synthetic teichoic acid conjugate vaccine against nosocomial Gram-positive bacteriaAnti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants.Neonatal infectious diseases: evaluation of neonatal sepsis.Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens.Vaccine protection of leukopenic mice against Staphylococcus aureus bloodstream infectionMechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection.Assessment of safety in newborns of mothers participating in clinical trials of vaccines administered during pregnancy.Isolation of highly active monoclonal antibodies against multiresistant gram-positive bacteria.Protein A-neutralizing monoclonal antibody protects neonatal mice against Staphylococcus aureus.Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.Global antibody response to Staphylococcus aureus live-cell vaccinationTargeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus DiseaseSuccessful selection of an infection-protective anti-Staphylococcus aureus monoclonal antibody and its protective activity in murine infection modelsPrevention and treatment of Staphylococcus aureus biofilms.Targeting pili in enterococcal pathogenesis.Alternatives to conventional antimicrobial drugs: a review of future prospects.Staphylococcus aureus Colonization: Modulation of Host Immune Response and Impact on Human Vaccine Design.Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.Late-onset sepsis in preterm infants: update on strategies for therapy and prevention.Adaptive Immunity Against Staphylococcus aureus.Vaccines for Healthcare-associated Infections: Promise and Challenge.Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention.[Multidrug-resistant bacteria in Germany. The impact of sources outside healthcare facilities].Detection of opsonic antibodies against Enterococcus faecalis cell wall carbohydrates in immune globulin preparations.From an evolutionary perspective, all 'new' antimicrobial targets are old: time to think outside the box.Infective endocarditis.Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis.Antibody-Based Agents in the Management of Antibiotic-Resistant Staphylococcus aureus Diseases.Immunomodulation to Prevent or Treat Neonatal Sepsis: Past, Present, and Future
P2860
Q26780246-5ED5546F-411A-4438-972A-6EDBBBB6B705Q26798461-CDC27C6D-DFA9-415F-80E1-A0F0B5931144Q26824837-514F3FCC-C7FA-4302-B07A-15715FDE364BQ26828726-8AECC7B2-45C6-426D-A8FA-5B1F094A779CQ28543983-66273119-C556-406C-8E1A-107C39D609FFQ30300455-65B4F036-A524-457C-B29F-A15205498BFEQ34332344-26E1691A-A2BA-48E2-91DC-EA5EFAFF251CQ34450382-83E991A9-DED5-4922-BE2B-53B12A4374A2Q34596203-731C87C9-BD9E-47C0-A636-766E7E018F17Q34792962-D0064410-E9D4-43D0-8467-038E18BDC463Q34999911-A29A0050-3110-4969-B69D-38A5FBF4D571Q35112655-AA9DD69D-5158-4EEB-A6A1-D93CA99E95C4Q35229922-B12B80C3-CC42-4C10-A59B-92AA51F190B4Q35736907-791E9012-607C-4F3C-8DA6-A0D6596A861AQ36609408-404C97F5-FCC1-49EC-8EC3-5117B27FC38EQ36824281-FA4F5AAD-E524-43E0-8B09-4C4EE3B50279Q37075941-D6F59C70-DD7E-463D-ABBA-7A5B594AB0C2Q37269558-519366B8-9617-403E-BE0C-5BE182506D64Q37482155-DCA7EAE0-CD5F-44A1-800A-0DE8C8DE3681Q37713275-DA762B33-3610-4C5F-ABA4-59ADB343A4D0Q37992684-6D1F28B0-3B13-40B8-AB76-B547DAEEA13BQ38177271-040521C9-AEE0-407A-9015-2E364509D284Q38291356-D71D45DF-0FB9-40CD-A212-0195C2C056A3Q38347714-AC9BC610-EA95-428A-A9EA-ECF79E0B4CADQ38751767-785BA3DD-9210-4516-A2F0-8D9E17780877Q40665389-63FCF248-77B0-4B69-8064-F8C8B5D2156BQ40697398-49C39C67-F135-484C-BF0E-96D174187C91Q40962124-1A2DB92B-B388-42DD-8AB8-296C9C3F4202Q42214164-C5E3EE8E-1F5C-4A3C-8D1F-8642D360C5B6Q43122369-30F31051-A730-467E-A3FC-06D91D058B80Q52943386-A40747FD-F3E3-449B-9F59-DE5733D5A764Q53122163-A871368F-23F1-4EA7-9265-8A639C08516CQ53702468-26AF6017-F148-45D8-8E2F-9B052EF4590FQ57175340-6C58BDAE-3F75-40C8-B463-D84CB02927F8
P2860
A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
A randomized study of a monocl ...... prevent staphylococcal sepsis.
@en
A randomized study of a monoclonal antibody
@nl
type
label
A randomized study of a monocl ...... prevent staphylococcal sepsis.
@en
A randomized study of a monoclonal antibody
@nl
prefLabel
A randomized study of a monocl ...... prevent staphylococcal sepsis.
@en
A randomized study of a monoclonal antibody
@nl
P2093
P356
P1433
P1476
A randomized study of a monocl ...... prevent staphylococcal sepsis.
@en
P2093
Beverly S Brozanski
Gerald W Fischer
H Cody Meissner
Helen M Thackray
Herbert A Lassiter
James J Mond
Jennifer Fretz
John F Kokai-Kun
Kristine G H Palmer
Leonard E Weisman
P304
P356
10.1542/PEDS.2010-3081
P407
P577
2011-07-25T00:00:00Z